295 related articles for article (PubMed ID: 16540689)
1. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort.
Belinsky SA; Liechty KC; Gentry FD; Wolf HJ; Rogers J; Vu K; Haney J; Kennedy TC; Hirsch FR; Miller Y; Franklin WA; Herman JG; Baylin SB; Bunn PA; Byers T
Cancer Res; 2006 Mar; 66(6):3338-44. PubMed ID: 16540689
[TBL] [Abstract][Full Text] [Related]
2. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment.
Hsu HS; Chen TP; Wen CK; Hung CH; Chen CY; Chen JT; Wang YC
J Pathol; 2007 Dec; 213(4):412-9. PubMed ID: 17973238
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer.
Machida EO; Brock MV; Hooker CM; Nakayama J; Ishida A; Amano J; Picchi MA; Belinsky SA; Herman JG; Taniguchi S; Baylin SB
Cancer Res; 2006 Jun; 66(12):6210-8. PubMed ID: 16778195
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program.
Baryshnikova E; Destro A; Infante MV; Cavuto S; Cariboni U; Alloisio M; Ceresoli GL; Lutman R; Brambilla G; Chiesa G; Ravasi G; Roncalli M
Clin Cancer Res; 2008 Mar; 14(6):1913-9. PubMed ID: 18347195
[TBL] [Abstract][Full Text] [Related]
5. Predicting lung cancer by detecting aberrant promoter methylation in sputum.
Palmisano WA; Divine KK; Saccomanno G; Gilliland FD; Baylin SB; Herman JG; Belinsky SA
Cancer Res; 2000 Nov; 60(21):5954-8. PubMed ID: 11085511
[TBL] [Abstract][Full Text] [Related]
6. Gene-promoter hypermethylation as a biomarker in lung cancer.
Belinsky SA
Nat Rev Cancer; 2004 Sep; 4(9):707-17. PubMed ID: 15343277
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications.
Liu Y; An Q; Li L; Zhang D; Huang J; Feng X; Cheng S; Gao Y
Carcinogenesis; 2003 Dec; 24(12):1897-901. PubMed ID: 12970072
[TBL] [Abstract][Full Text] [Related]
8. Anthracotic index and DNA methylation status of sputum contents can be used for identifying the population at risk of lung carcinoma.
Konno S; Morishita Y; Fukasawa M; Shu Y; Wang D; Tanaka R; Minami Y; Iijima T; Noguchi M
Cancer; 2004 Dec; 102(6):348-54. PubMed ID: 15481085
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation analysis: a powerful new tool for lung cancer diagnosis.
Tsou JA; Hagen JA; Carpenter CL; Laird-Offringa IA
Oncogene; 2002 Aug; 21(35):5450-61. PubMed ID: 12154407
[TBL] [Abstract][Full Text] [Related]
10. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
12. Molecular diagnostic markers for lung cancer in sputum and plasma.
Wang YC; Hsu HS; Chen TP; Chen JT
Ann N Y Acad Sci; 2006 Sep; 1075():179-84. PubMed ID: 17108209
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
14. A case-cohort study of an early biomarker of lung cancer in a screening cohort of Yunnan tin miners in China.
Qiao YL; Tockman MS; Li L; Erozan YS; Yao SX; Barrett MJ; Zhou WH; Giffen CA; Luo XC; Taylor PR
Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):893-900. PubMed ID: 9367062
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
16. Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC.
Olaussen KA; Soria JC; Park YW; Kim HJ; Kim SH; Ro JY; André F; Jang SJ
Eur J Cancer; 2005 Sep; 41(14):2112-9. PubMed ID: 16129599
[TBL] [Abstract][Full Text] [Related]
17. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
18. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
[TBL] [Abstract][Full Text] [Related]
19. Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity.
Byers T; Wolf HJ; Franklin WA; Braudrick S; Merrick DT; Shroyer KR; Hirsch FR; Zeng C; Barón AE; Bunn PA; Miller YE; Kennedy TC
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):158-62. PubMed ID: 18199720
[TBL] [Abstract][Full Text] [Related]
20. [Aberrant promoter methylation as biomarker for molecular cytological diagnosis of lung cancer].
Grote HJ
Verh Dtsch Ges Pathol; 2006; 90():216-26. PubMed ID: 17867600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
